The US Meals and Drug Administration right now authorized a capsule model of the blockbuster anti-obesity drug Wegovy. Made by Novo Nordisk, the capsule is taken as soon as a day. The corporate’s unique model of Wegovy is a weekly injection. Each medication comprise the identical energetic ingredient, semaglutide.
“This enables sufferers with weight problems who need to drop a few pounds to have a alternative between a as soon as weekly injection or a each day pill,” says Martin Holst Lange, chief scientific officer at Novo Nordisk.
With the hovering reputation of injectable GLP-1 medication for weight reduction, Novo Nordisk and different pharmaceutical corporations have been racing to make efficient capsule variations that might be preferable for some sufferers. These medication mimic a naturally occurring hormone within the physique that acts on the mind and intestine to advertise a sense of fullness.
In scientific trial outcomes revealed within the New England Journal of Drugs, individuals who took the capsule achieved a median weight lack of 13.6 p.c by 64 weeks. Practically 30 p.c of individuals misplaced 20 p.c or extra of their weight. The research additionally confirmed enhancements in heart problems threat and bodily exercise ranges much like the injectable model.
Whereas capsules can typically be a extra handy choice, sufferers might not at all times take them as prescribed, making them much less efficient. The scientific trial investigators estimated that in a great state of affairs the place individuals take the capsule day by day as prescribed, weight reduction could be 16.6 p.c—which has similarities to outcomes seen with injectable Wegovy.
Novo Nordisk first received approval for an oral semaglutide, offered underneath the model title Rybelsus, in 2019 to deal with sort 2 diabetes. That drug has by no means been authorized for weight problems and isn’t as efficient for weight reduction as newer GLP-1 medicines. The Wegovy capsule is basically a higher-dose model of Rybselsus.
“The efficacy for the weight problems capsule on the finish of the day is pushed by dose. Larger doses are required to realize full weight-loss potential for weight problems,” Lange says. The Wegovy capsule is 25 milligrams whereas Rybelsus is 14 milligrams.
The commonest unintended effects of oral Wegovy embody nausea and vomiting, that are additionally unintended effects of the injectable model.
Novo says the beginning dose of the capsule, 1.5 milligrams, might be obtainable in early January for $149 monthly with financial savings affords. Manufacturing of the remedy is already underway at Novo Nordisk’s US manufacturing websites, and the corporate expects to have sufficient of the drug to fulfill US demand.
